Hamamatsu introduces InGaAs PIN photodiodes  by unknown
InGaAs PIN photodiodes with
typical sensitivity ranging from
+2 dBm to -20 dBm at 1.55um
have been introduced by
Hamamatsu Corporation with
its G9911-14/-54 receiver opti-
cal sub-assemblies (ROSAs).
These have high-speed
response, high trans-impedance,
low optical return loss, and
excellent sensitivity. Compatible
with 10Gbps miniature devices
(XMD), the G9911-14/-54 are
designed for use in XFP trans-
ceivers, as well as SONET/SDH
network applications.
The G9911-14/-54 have high
trans-impedance of typically 6
kOhms and low optical return
loss of typically 35 dB at both
1.31 um and 1.55 um.Typical
response is 0.85 A/W at 1.31
um and 0.9 A/W at 1.55 um,
and the G9911-14/-54 have typ-
ical dark current of 0.05 nA.
Requiring only 3.3 V, these are
low power devices that provide
flexibility in design of XFP
transceivers.The G9911-14 has
a pin design while the G9911-
54 incorporates a flex board
interface for space-restricted
designs.
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Light BioScience has US Food
and Drug Administration (FDA)
clearance for its GentleWaves
LED Photomodulation system
for the non-invasive treatment
of periorbital (eye area) wrin-
kles and rhytids.
It claims to be the first and
only LED device to receive
marketing approval for a med-
ical claim associated with cos-
metic improvement of aging
and sun-damaged skin, further
validating the science of LED
Photomodulation for skin 
rejuvenation.
“This is a fundamentally new
approach to improving photo-
aging and environmentally
damaged skin that does not
rely on high-energy sources
and heat damage to photoacti-
vate collagen genes,” said
Robert Weiss, MD, associate
professor of dermatology at
Johns Hopkins University
School of Medicine in
Baltimore, Maryland.
“For the first time, we are both
slowing down collagen break-
down and building up new 
Light BioScience LEDs get FDA nod 
collagen with no pain, no red-
ness and no serious side effects.
GentleWaves’ unique ability to
stimulate and/or inhibit cell sig-
naling pathways for skin rejuve-
nation truly represents the next
frontier in anti-aging medicine,”
he added.
GentleWaves uses specially
coded arrays of LEDs to 
modulate the activity of living
cells. Unlike other laser, pulsed
light or radiofrequency 
techniques used today for 
skin rejuvenation, this core
technology delivers very 
low-intensity, non-thermal light
energy to stimulate collagen
and reverse the appearance 
of photoaging.
With its proprietary and prede-
termined energy sequencing,
the easy-to-use device poses no
learning curve or risk of compli-
cations.A patient simply sits
with his/her face exposed to
two panels of over 2,000 yellow
cascading LED lights for less
than one minute.The device
can also be adjusted to treat the
neck and chest areas.
According to lead researcher
David McDaniel, MD, the FDA
clearance marks the culmina-
tion of years of rigorous 
scientific investigation and 
successful clinical practice by
renowned aesthetic physicians
nationwide.
Evident Technologies has put
the package up front with
EviComposites: quantum dots
of II-VI, III-V, or IV-VI material,
integrated into a series of com-
mon resins and polymer matrix
materials widely used in many
commercial manufacturing
processes and products.
Evident engineered its propri-
etary EviDot quantum dots into
a series of new easy-to-use
forms designed to speed the
development of new materials
and new products by making
QDs of materials more applica-
ble to common manufacturing
processes.
“Quantum dots can be fragile
and hard to functionalise but
the focus of our business has
always been on stabilising
them so they become more
highly functional and easy to
use,” said Clint Ballinger,
Evident Technologies CEO.
"Putting our proprietary QDs
into a range of common plastic
materials accomplishes this on
a broad scale, bridges a critical
gap in the field, and can expand
and accelerate the use of QDs
in creating new products."
EviComposites have wide
applicability for applications
ranging from paints, inks,
molded parts, films, fibers,
solar cells, optical standards or
numerous other areas.The
EviComposite resins are avail-
able in UV curable clear
resins, as well as thermal and
UV Sol-gels.
The EviComposite particles
and powders are available in
polycarbonates, polystyrene,
Polymethyl Methacrylate
(PMMA) and polyethylene in
quantities from 1g to kgs.
EviComposites come in colors
ranging from blue to into reds,
with a selected set of polymers
in the near IR.
"A critical problem with any
emerging technology is driv-
ing trial usage, which in turn
drives application develop-
ment and market growth,” says
Sean Murdock, executive
director of the NanoBusiness
Alliance.
“To the extent that
EviComposites are able to
retain the nanoscale phenome-
na of quantum dots in a 'con-
ventional' material toolkit, it
will accelerate the adoption of
the technology by reducing the
learning curve and transaction
cost of trial usage.”
Evident embeds QD in plastic
